Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and ...

All 20 assets are trading higher. Leaders: RENDER (+13.5%) and ETC (+11.3%). Laggards: BTC (+2.4%) and ETH (+2.6%). The <a ...

With a median follow-up of 14.1 months, adding tafasitamab to lenalidomide and rituximab reduced the risk of progression, ...

The CoinDesk 20 is currently trading at 3857.2, down 3.7% (-150.02) since 4 pm on Friday. One of 20 assets are trading higher ...

Since the Fed's easing cycle began coupled with the outcome of the U.S. election, digital assets have experienced significant ...

Avalanche, the layer-1 blockchain that is upgrading its technology platform, has raised $250 million in a token sale led by ...

Innate Pharma & IFLI enter agreement to clinically study the potential of IPH6501, Innate's anti-CD20 ANKET in follicular lymphoma: Marseille, France Monday, December 9, 2024, 13: ...

The 5-year results of the POLARIX study show a continued progression-free survival benefit for patients with diffuse large ...

Ordspono is a CD20xCD3 bispecific monoclonal antibody that facilitates T cell engagement for the targeted killing of ...

Researchers review the safety, efficacy, and considerations for COVID-19 vaccination in multiple sclerosis patients, ...

ImmunityBio faces competition but offers strong potential with Anktiva. See why IBRX stock remains a buy, backed by a ...

Roche’s Lunsumio may be the first CD20xCD3 T-cell engager approved by the FDA, but intravenous administration puts the drug ...